Cargando…

Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence

The aim of the present critical review is to summarize the available clinical evidence supporting the use of some dietary supplements that have been shown to lower blood pressure in hypertensive pregnant women. A systematic search strategy was carried out to identify trials in MEDLINE (National Libr...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogacci, Silvia, Fogacci, Federica, Cicero, Arrigo F.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071166/
https://www.ncbi.nlm.nih.gov/pubmed/32023928
http://dx.doi.org/10.3390/nu12020378
_version_ 1783506139084750848
author Fogacci, Silvia
Fogacci, Federica
Cicero, Arrigo F.G.
author_facet Fogacci, Silvia
Fogacci, Federica
Cicero, Arrigo F.G.
author_sort Fogacci, Silvia
collection PubMed
description The aim of the present critical review is to summarize the available clinical evidence supporting the use of some dietary supplements that have been shown to lower blood pressure in hypertensive pregnant women. A systematic search strategy was carried out to identify trials in MEDLINE (National Library of Medicine, Bethesda, Maryland, MD, USA; January 1980 to September 2019) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). The terms ‘nutraceuticals’, ‘dietary supplements’, ‘pregnancy’, ‘pre-eclampsia’, ‘clinical trial’, and ‘human’ were incorporated into an electronic search strategy. The references of the identified studies and review articles were reviewed to look for additional studies of interest. We preferably selected papers that reported recent comprehensive reviews or meta-analysis, or original clinical trials of substances with blood pressure-lowering or vascular protective effect in pregnancy. There is a relative body of evidence that supports the use of calcium, vitamin D, folic acid, and resveratrol in preventing the development of hypertensive disorders in pregnancy, and evidence supporting drug treatment too. Further clinical research is advisable to identify the dosage and timing of the supplementation, the group of women that might benefit the most from this approach, and the nutraceuticals with the best cost-effectiveness and risk-benefit ratio for widespread use in clinical practice.
format Online
Article
Text
id pubmed-7071166
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70711662020-03-19 Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence Fogacci, Silvia Fogacci, Federica Cicero, Arrigo F.G. Nutrients Review The aim of the present critical review is to summarize the available clinical evidence supporting the use of some dietary supplements that have been shown to lower blood pressure in hypertensive pregnant women. A systematic search strategy was carried out to identify trials in MEDLINE (National Library of Medicine, Bethesda, Maryland, MD, USA; January 1980 to September 2019) and the Cochrane Register of Controlled Trials (The Cochrane Collaboration, Oxford, UK). The terms ‘nutraceuticals’, ‘dietary supplements’, ‘pregnancy’, ‘pre-eclampsia’, ‘clinical trial’, and ‘human’ were incorporated into an electronic search strategy. The references of the identified studies and review articles were reviewed to look for additional studies of interest. We preferably selected papers that reported recent comprehensive reviews or meta-analysis, or original clinical trials of substances with blood pressure-lowering or vascular protective effect in pregnancy. There is a relative body of evidence that supports the use of calcium, vitamin D, folic acid, and resveratrol in preventing the development of hypertensive disorders in pregnancy, and evidence supporting drug treatment too. Further clinical research is advisable to identify the dosage and timing of the supplementation, the group of women that might benefit the most from this approach, and the nutraceuticals with the best cost-effectiveness and risk-benefit ratio for widespread use in clinical practice. MDPI 2020-01-31 /pmc/articles/PMC7071166/ /pubmed/32023928 http://dx.doi.org/10.3390/nu12020378 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fogacci, Silvia
Fogacci, Federica
Cicero, Arrigo F.G.
Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title_full Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title_fullStr Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title_full_unstemmed Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title_short Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence
title_sort nutraceuticals and hypertensive disorders in pregnancy: the available clinical evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071166/
https://www.ncbi.nlm.nih.gov/pubmed/32023928
http://dx.doi.org/10.3390/nu12020378
work_keys_str_mv AT fogaccisilvia nutraceuticalsandhypertensivedisordersinpregnancytheavailableclinicalevidence
AT fogaccifederica nutraceuticalsandhypertensivedisordersinpregnancytheavailableclinicalevidence
AT ciceroarrigofg nutraceuticalsandhypertensivedisordersinpregnancytheavailableclinicalevidence